MedWatch

Analyst: Novo Nordisk's year may start with zero growth

Last year's stockpiling at the start of the covid-19 pandemic provides difficult grounds for comparison for Novo Nordisk, which publicizes its Q1 report on Wednesday.

Photo: Stine Tidsvilde

Although covid-19 restrictions are slowly easing up, Danish financial institution Sydbank believes that pharmaceutical company Novo Nordisk's growth will be kept down by the crisis.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Latest news

See all jobs